Indications
Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.
Composition
- Active substance
- fluticasone propionate, salmeterol xinafoate
- International name (INN)
- salmeterol;fluticasone propionate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Seffalair Spiromax
- Active substance
- fluticasone propionate, salmeterol xinafoate
- ATC code
- R03AK06
- Group
- Respiratory system
- Therapeutic area
- Asthma